Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice
- PMID: 30871282
- PMCID: PMC6470758
- DOI: 10.3390/ijms20061273
Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice
Abstract
The risk of heart failure (HF) is prominently increased in patients with type 2 diabetes mellitus. The objectives of this study were to establish a murine model of diabetic cardiomyopathy induced by feeding a high-sugar/high-fat (HSHF) diet and to evaluate the effect of reconstituted HDLMilano administration on established HF in this model. The HSHF diet was initiated at the age of 12 weeks and continued for 16 weeks. To investigate the effect of reconstituted HDLMilano on HF, eight intraperitoneal administrations of MDCO-216 (100 mg/kg protein concentration) or of an identical volume of control buffer were executed with a 48-h interval starting at the age of 28 weeks. The HSHF diet-induced obesity, hyperinsulinemia, and type 2 diabetes mellitus. Diabetic cardiomyopathy was present in HSHF diet mice as evidenced by cardiac hypertrophy, increased interstitial and perivascular fibrosis, and decreased myocardial capillary density. Pressure-volume loop analysis indicated the presence of both systolic and diastolic dysfunction and of decreased cardiac output in HSHF diet mice. Treatment with MDCO-216 reversed pathological remodelling and cardiac dysfunction and normalized wet lung weight, indicating effective treatment of HF. No effect of control buffer injection was observed. In conclusion, reconstituted HDLMilano reverses HF in type 2 diabetic mice.
Keywords: diabetic cardiomyopathy; obesity; type 2 diabetes mellitus.
Conflict of interest statement
The authors declare no conflict of interest. Herman Kempen was an employee of The Medicines Company (Schweiz) GmbH between 2011 and 2015 and retired subsequently. He does not benefit in any financial manner from being a co-author on this paper. None of the other authors received any financial support of The Medicines Company.
Figures








Similar articles
-
Reconstituted HDL (Milano) Treatment Efficaciously Reverses Heart Failure with Preserved Ejection Fraction in Mice.Int J Mol Sci. 2018 Oct 30;19(11):3399. doi: 10.3390/ijms19113399. Int J Mol Sci. 2018. PMID: 30380754 Free PMC article.
-
Cholesterol-Lowering Gene Therapy Prevents Heart Failure with Preserved Ejection Fraction in Obese Type 2 Diabetic Mice.Int J Mol Sci. 2019 May 6;20(9):2222. doi: 10.3390/ijms20092222. Int J Mol Sci. 2019. PMID: 31064116 Free PMC article.
-
Successful treatment of established heart failure in mice with recombinant HDL (Milano).Br J Pharmacol. 2018 Nov;175(21):4167-4182. doi: 10.1111/bph.14463. Epub 2018 Sep 19. Br J Pharmacol. 2018. PMID: 30079544 Free PMC article.
-
The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?Pharmacol Ther. 2022 Apr;232:108008. doi: 10.1016/j.pharmthera.2021.108008. Epub 2021 Oct 2. Pharmacol Ther. 2022. PMID: 34610378 Review.
-
Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy.Adv Exp Med Biol. 2018;1067:197-217. doi: 10.1007/5584_2017_105. Adv Exp Med Biol. 2018. PMID: 28980272 Review.
Cited by
-
Mitochondria-associated endoplasmic reticulum membrane (MAM): a dark horse for diabetic cardiomyopathy treatment.Cell Death Discov. 2024 Mar 20;10(1):148. doi: 10.1038/s41420-024-01918-3. Cell Death Discov. 2024. PMID: 38509100 Free PMC article. Review.
-
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure.Circulation. 2020 May 5;141(18):1463-1476. doi: 10.1161/CIRCULATIONAHA.119.045323. Epub 2020 Apr 2. Circulation. 2020. PMID: 32237898 Free PMC article.
-
The Mitochondria: A Target of Polyphenols in the Treatment of Diabetic Cardiomyopathy.Int J Mol Sci. 2020 Jul 14;21(14):4962. doi: 10.3390/ijms21144962. Int J Mol Sci. 2020. PMID: 32674299 Free PMC article. Review.
-
HDL Composition, Heart Failure, and Its Comorbidities.Front Cardiovasc Med. 2022 Mar 8;9:846990. doi: 10.3389/fcvm.2022.846990. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35350538 Free PMC article. Review.
-
Advances in HDL: Much More than Lipid Transporters.Int J Mol Sci. 2020 Jan 22;21(3):732. doi: 10.3390/ijms21030732. Int J Mol Sci. 2020. PMID: 31979129 Free PMC article. Review.
References
-
- Authors/Task Force Members. Ryden L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.P., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur. Heart J. 2013;34:3035–3087. doi: 10.1093/eurheartj/eht108. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous